There’s been a lot of buzz the last few days about reviving the dead via stem cells. Is this possible? Who knows, but it would be very long odds. Could it lead to zombies? Not really, but there could be negative outcomes even if it seems to sorta work (more below). Bioquark, Inc. is a […]
Beyond zombies: reviving dead people with stem cells & lasers? Read More »
Blood testing biotech Theranos finds itself in a hole that seemingly just keeps getting deeper with the report today that the company is under criminal investigation. Can it bounce back? Some people are really upset with Theranos for allegedly making misleading statements including both to investors and the government about its technologies. It’s no exaggeration
Will there be a Theranos of the stem cell field? Read More »
There’s been an interesting and diverse discussion going on here on this blog lately related to some stem cell translational things including a stem cell clinic operating in Sacramento (see 50+ comments on that post) and then more recently on a new paper from the Centeno clinic. .@pknoepfler Did most (or all) participants in this study pay
Do for-profit stem cell studies have inherent potential biases? Read More »
There is considerable interest in FDA regulatory reform here in the U.S. for stem cell therapies. The goal is to get new treatments to patients faster, but is there a way to do that without sacrificing proven safety and efficacy? You need convincing data on both safety and efficacy or speed becomes dangerous. Bipartisan Policy Center
Cons Outweigh Potential Pros to BPC Plan on Stem Cells & FDA Read More »
A team at the University of Miami has launched a claimed first of its kind stem cell clinic trial for Alzheimer’s Disease (AD). The trial seems somewhat unique in using mesenchymal stem cells (MSC) for AD and is being run with biotech Longeveron. You can read more on the actual clinic trial including all the
New Stem Cell Clinic Trial for Alzheimer’s: Perspectives & Questions Read More »
There has been a lot of excitement this week about a press release from stem cell biotech Athersys that reported that treatment of stroke patients with its product MultiStem was associated with a statistically significant improvement at 1-year. This sounds encouraging and the stock has spiked up as a result. However, there are some naysayers
About that Athersys stem cell stroke clinic trial PR… Read More »
The FDA in the past year or so has issued draft guidances on regulation of stem cells that would, if finalized, make it crystal clear that what many American stem cell clinics are selling are unapproved drugs. That would be a good thing for patients who are often being put at risk by many of
FDA meeting on stem cell regs: mostly who’s who of anti-regulation forces Read More »
California stem cell biotech, StemCells, Inc. ($STEM), has really struggled for years and its stock is now flatlining raising the question: can it cheat death? Will 2016 be the year that STEM turns things around? So far this year hasn’t started off that well. You can see the graph at right from today on the
Can StemCells Inc. Cheat Death? Read More »
I try to catch up on my science reading over the weekends and evenings. Here’s my recommended weekend reading on stem cells & science. Did I miss anything especially cool? Let me know in the comments. Direct reprogramming of skin cells into insulin-producing cells. I love direct reprogramming. Healios and Athersys Enter Into Regenerative Medicine Partnership.
Recommended weekend reading on stem cells & science Read More »
What will the new year have in store for stem cells? 2016 promises to have many striking stem cell developments. Below are my top 20 stem cell predictions for what is to come this year in no particular order. Share your stem cell tea leaves in the comments please. Another stem cell biotech acquisition by pharma
List of 20 stem cell predictions for 2016 Read More »